April 17, 2025
NOTICE TO ATTEND ANNUAL GENERAL MEETING
ON MAY 21, 2025 IN ISOFOL MEDICAL AB (PUBL)
April 11, 2025
ANNUAL REPORT AND CORPORATE GOVERNANCE REPORT
FOR THE FINANCIAL YEAR 2024 ARE NOW AVAILABLE
April 3, 2025
ISOFOL’S PARTNER SOLASIA INTENDS TO INCREASE
INVESTMENTS IN UPCOMING TRIALS WITH ARFOLITIXORIN
March 21, 2025
ISOFOL RECEIVES REGULATORY APPROVAL
TO INITIATE CLINICAL STUDY OF ARFOLITIXORIN
About Isofol
Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company’s drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world’s third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with new dosing regimens that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- May 21, 2025 - May 21, 2025
Interim report January-March 2025 - May 21, 2025 - May 22, 2025
Annual General Meeting 2025, Gothenburg - July 18, 2025 - July 18, 2025
Interim report April-June 2025
Media – Lates pressreleases
Notice to attend the Annual General Meeting held on May 21, 2025 in Isofol Medical AB (publ)
GOTHENBURG, Sweden, April 17, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No….
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2024
GOTHENBURG, Sweden, April 11, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report and corporate governance report…
Isofol’s partner Solasia intends to increase investments in upcoming trials with arfolitixorin
GOTHENBURG, Sweden, April 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company’s Japanese development and commercialization partner, Solasia Pharma…
INVESTORS – latest reports and presentations
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.
